The c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program
Abstract
Cell death processes are progressively inactivated during malignant development, in part by loss of tumor suppressors that can promote cell death. The Bin1 gene encodes a nucleocytosolic adaptor protein with tumor suppressor properties, initially identified through its ability to interact with and inhibit malignant transformation by c-Myc and other oncogenes. Bin1 is frequently missing or functionally inactivated in breast and prostate cancers and in melanoma. In this study, we show that Bin1 engages a caspase-independent cell death process similar to type II apoptosis, characterized by cell shrinkage, substratum detachment, vacuolated cytoplasm, and DNA degradation. Cell death induction was relieved by mutation of the BAR domain, a putative effector domain, or by a missplicing event that occurs in melanoma and inactivates suppressor activity. Cells in all phases of the cell cycle were susceptible to death and p53 and Rb were dispensable. Notably, Bin1 did not activate caspases and the broad spectrum caspase inhibitor ZVAD.fmk did not block cell death. Consistent with the lack of caspase involvement, dying cells lacked nucleosomal DNA cleavage and nuclear lamina degradation. Moreover, neither Bcl-2 or dominant inhibition of the Fas pathway had any effect. In previous work, we showed that Bin1 could not suppress cell transformation by SV40 large T antigen. Consistent with this finding, we observed that T antigen suppressed the death program engaged by Bin1. This observation wa…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A large proportion of BIN1 expressed in the brain may not participate in clathrin-mediated endocytosis.
“these observations raise the possibility that large proportion of BIN1 expressed in the brain may not participate in clathrin-mediated endocytosis [54].”
From Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts (2016) · cites this paper as [54]
The CLAP domain is required for BIN1 interaction with clathrin.
“Since the CLAP domain is required for BIN1 interaction with clathrin”
From Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts (2016) · cites this paper as [54]
Cites
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345 · see citing works
Butler, M. H., David, C., Ochoa, G.-C., Freyberg, Z., Daniell, L., Grabs, D., Cremona, O., & Camilli, P. D. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.6.1355 · Cited by 256 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064 · see citing works
De Rossi, P., Buggia-Prévot, V., Clayton, B. L. L., Vasquez, J. B., van Sanford, C., Andrew, R. J., Lesnick, R., Botté, A., Deyts, C., Salem, S., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0124-1 · Cited by 151 · see citing works
“Since the CLAP domain is required for BIN1 interaction with clathrin, these observations raise the possibility that large proportion of BIN1 expressed in the brain may not participate in clathrin-mediated endocytosis [54].”
Taga, M., Petyuk, V. A., White, C., Marsh, G., Ma, Y., Klein, H.-U., Connor, S. M., Kroshilina, A., Yung, C. J., Khairallah, A., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00387-3 · Cited by 81 · see citing works
Bin1 Interacts with and Restrains the DNA End-Binding Protein Complex Ku
Ramalingam, A., Farmer, G. E., Stamato, T., & Prendergast, G. C. (2007) · Cell Cycle · doi:10.4161/cc.6.15.4514 · Cited by 18 · see citing works
Self-citation
- Authors
- Elliott, K., Ge, K., Du, W., & Prendergast, G. C.
- Affiliations
- The Wistar Institute (US)
- Venue
- Oncogene
- Published
- 2000-09-28
- Volume
- 19
- Issue
- 41
- Pages
- 4669-4684
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2030844021
- Cited by
- 106
- References
- 2
- Citations by year
- 2025: 5 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 7 · 2019: 3 · 2018: 2 · 2017: 3 · 2016: 1 · 2015: 4 · 2014: 3 · 2013: 3 · 2012: 1
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- BIN1, c-Myc, caspase-independent cell death, tumor suppressor, BAR domain, aberrant splicing, SV40 large T antigen, cell transformation, DNA degradation, melanoma, prostate cancer, breast cancer, cell cycle, serine protease inhibition, AEBSF
- MeSH terms
- Amino Acid Chloromethyl Ketones, Antigens, Polyomavirus Transforming, Bone Neoplasms, Carrier Proteins, Cell Adhesion, Cell Transformation, Neoplastic, Enzyme Activation, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Mitochondria, Nuclear Proteins, Recombinant Fusion Proteins, Osteosarcoma, Sulfones, Tumor Cells, Cultured, Serine Proteinase Inhibitors, Cysteine Proteinase Inhibitors, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Retinoblastoma Protein, Proto-Oncogene Proteins c-myc, Apoptosis, Protein Structure, Tertiary, fas Receptor, Proto-Oncogene Proteins c-bcl-2, Caspases, Tumor Suppressor Proteins, Cell Size, Adaptor Proteins, Signal Transducing, DNA Fragmentation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review